Surge, a Paris, France-based company which specializes in high-dimensional immune system analysis combined with artificial intelligence, raised €7.5M in funding.
The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov’, as well as Boutique Venture, HCVC, and 50 Partners Santé.
The company intends to use the funds to enable the opening of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, and the finalization of PreCyte®‘s industrialization.
Surge provides a high-dimensional immune system analysis combined with artificial intelligence. With the launch of PreCyte®, its flagship product predicting post-operative complications, and the inauguration of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, the company aims to transform healthcare pathways, optimize patient care, and reduce hospitalization stays.
FinSMEs
28/03/2024